STAT+: I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned

Anthropic's CEO Dario Amodei revised his timeline for AI's impact on biotech, acknowledging that current AI tools may not yet enable the rapid progress he previously predicted. He cited limitations in model capabilities, the need for researchers to adapt to new tools, and slow infrastructure/regulatory changes as barriers. Anthropic introduced a biotech-focused product called Claude Science during an event.